Adam H Fox1, James R Jett2, Upal Basu Roy3, Bruce E Johnson4, Jennifer C King5, Nikki Martin3, Raymond U Osarogiagbon6, M Patricia Rivera7, Lauren S Rosenthal8, Robert A Smith8, Gerard A Silvestri9. 1. Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. 2. Biodesix Inc, Boulder, CO. 3. LUNGevity Foundation, Bethesda, MD. 4. Dana-Farber Cancer Institute, Boston, MA. 5. GO2 Foundation for Lung Cancer, Washington, DC. 6. Baptist Cancer Center, Memphis, TN. 7. Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. 8. Prevention and Early Detection Department, American Cancer Society, Atlanta, GA. 9. Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. Electronic address: silvestr@musc.edu.
Abstract
BACKGROUND: Targeted therapies for advanced non-small cell lung cancer (NSCLC) with oncogenic drivers have caused a paradigm shift in care. Biomarker testing is needed to assess eligibility for these therapies. Pulmonologists often perform bronchoscopy, providing tissue for both pathologic diagnosis and biomarker analysis. We performed this survey to define the existing knowledge and practices regarding the pulmonologists' role in biomarker testing for advanced NSCLC. RESEARCH QUESTION: What is the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced NSCLC? STUDY DESIGN AND METHODS: This cross-sectional study was performed using an electronic survey of a random sample of 7,238 pulmonologists. Questions focused on diagnostic steps and biomarker analyses for NSCLC. RESULTS: A total of 453 pulmonologists responded. Respondents vary by reported lung cancer patient volume, ranging from 51% evaluating one to four new cases per month to 19% evaluating > 10 cases per month. Interventional training, academic practice setting, and higher volume of endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) were associated with increased knowledge of practice guidelines for the number of recommended passes during EBUS-TBNA (P < .05). Academic pulmonologists more commonly performed or referred for EBUS-TBNA than community pulmonologists (96% and 83%, respectively; P < .0005). Higher testing rates were associated with interventional training, academic setting, and the presence of an institutional policy, whereas lower testing rates were associated with general pulmonologists, practice in community settings, and lack of a guiding institutional policy (P < .05). INTERPRETATION: Substantial differences among pulmonologists' evaluation of advanced NSCLC, variation in knowledge of available biomarkers and the importance of targeted therapies, and differences in institutional coordination likely lead to underutilization of biomarker testing. Interventional training appears to drive improved knowledge and practice for biomarker testing more than practice setting. Improvements are needed in tissue acquisition and interdisciplinary coordination to ensure universal and comprehensive testing for eligible patients.
BACKGROUND: Targeted therapies for advanced non-small cell lung cancer (NSCLC) with oncogenic drivers have caused a paradigm shift in care. Biomarker testing is needed to assess eligibility for these therapies. Pulmonologists often perform bronchoscopy, providing tissue for both pathologic diagnosis and biomarker analysis. We performed this survey to define the existing knowledge and practices regarding the pulmonologists' role in biomarker testing for advanced NSCLC. RESEARCH QUESTION: What is the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced NSCLC? STUDY DESIGN AND METHODS: This cross-sectional study was performed using an electronic survey of a random sample of 7,238 pulmonologists. Questions focused on diagnostic steps and biomarker analyses for NSCLC. RESULTS: A total of 453 pulmonologists responded. Respondents vary by reported lung cancer patient volume, ranging from 51% evaluating one to four new cases per month to 19% evaluating > 10 cases per month. Interventional training, academic practice setting, and higher volume of endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) were associated with increased knowledge of practice guidelines for the number of recommended passes during EBUS-TBNA (P < .05). Academic pulmonologists more commonly performed or referred for EBUS-TBNA than community pulmonologists (96% and 83%, respectively; P < .0005). Higher testing rates were associated with interventional training, academic setting, and the presence of an institutional policy, whereas lower testing rates were associated with general pulmonologists, practice in community settings, and lack of a guiding institutional policy (P < .05). INTERPRETATION: Substantial differences among pulmonologists' evaluation of advanced NSCLC, variation in knowledge of available biomarkers and the importance of targeted therapies, and differences in institutional coordination likely lead to underutilization of biomarker testing. Interventional training appears to drive improved knowledge and practice for biomarker testing more than practice setting. Improvements are needed in tissue acquisition and interdisciplinary coordination to ensure universal and comprehensive testing for eligible patients.
Authors: Christina R Bellinger; Arjun B Chatterjee; Norman Adair; Tim Houle; Irtaza Khan; Edward Haponik Journal: Respiration Date: 2014-11-12 Impact factor: 3.580
Authors: P K Cheema; S Raphael; R El-Maraghi; J Li; R McClure; L Zibdawi; A Chan; J C Victor; A Dolley; A Dziarmaga Journal: Curr Oncol Date: 2017-02-27 Impact factor: 3.677
Authors: Sean Khozin; Gideon M Blumenthal; Xiaoping Jiang; Kun He; Karen Boyd; Anthony Murgo; Robert Justice; Patricia Keegan; Richard Pazdur Journal: Oncologist Date: 2014-05-27
Authors: Nadia Howlader; Gonçalo Forjaz; Meghan J Mooradian; Rafael Meza; Chung Yin Kong; Kathleen A Cronin; Angela B Mariotto; Douglas R Lowy; Eric J Feuer Journal: N Engl J Med Date: 2020-08-13 Impact factor: 91.245
Authors: Roy S Herbst; Giuseppe Giaccone; Filippo de Marinis; Niels Reinmuth; Alain Vergnenegre; Carlos H Barrios; Masahiro Morise; Enriqueta Felip; Zoran Andric; Sarayut Geater; Mustafa Özgüroğlu; Wei Zou; Alan Sandler; Ida Enquist; Kimberly Komatsubara; Yu Deng; Hiroshi Kuriki; Xiaohui Wen; Mark McCleland; Simonetta Mocci; Jacek Jassem; David R Spigel Journal: N Engl J Med Date: 2020-10-01 Impact factor: 91.245
Authors: Kathryn F Mileham; Caroline Schenkel; Suanna S Bruinooge; Janet Freeman-Daily; Upal Basu Roy; Amy Moore; Robert A Smith; Elizabeth Garrett-Mayer; Lauren Rosenthal; Edward B Garon; Bruce E Johnson; Raymond U Osarogiagbon; Shadia Jalal; Shamsuddin Virani; Mary Weber Redman; Gerard A Silvestri Journal: Cancer Med Date: 2021-12-17 Impact factor: 4.452